NYSE Content Update: Teradata AI Report Surveys 1,000 Global Tech + Data Leaders

Enterprise AI adoption remains early: 68% of enterprises are still experimenting/developing and only 7% have reached tangible-outcomes stage, per Teradata’s survey. In biotech, Annovis Bio said it completed full enrollment of 850 patients for its Phase 3 trial of Buntanetap in early Alzheimer’s. Overall, the items are incremental and informational, with a modest positive tilt driven by progress in AI rollout and clinical-stage execution.

Analysis

The most actionable signal here is not the survey result itself, but the gap it confirms between AI enthusiasm and monetization. If most buyers are still in pilot mode, the near-term beneficiaries are the vendors that get paid for integration, governance, security, and legacy-stack compatibility—not the names priced for immediate broad-based AI seat expansion. That favors IBM-style enterprise modernization franchises and keeps pressure on higher-multiple application software that needs rapid budget conversion to justify valuations.

Teradata’s data also implies a slower revenue recognition curve for the AI ecosystem: CIOs can keep spending in ways that inflate services and infrastructure demand while deferring durable software commitments. Over the next 1-3 months, that usually means “AI progress” headlines support sentiment, but earnings revisions matter more; if vendors cannot show pipeline-to-bookings conversion, the market will rotate from concept names to cash-generative infrastructure and consulting. In that frame, TDC is more credible as a thought-leadership vehicle than as evidence of an imminent growth inflection.

ANVS is a separate, binary clinical setup: full enrollment reduces one operational risk, but it does not de-risk efficacy or tolerability, which are what the stock will ultimately trade on. GS and the index-style fund anniversary notes are noise. Contrarian take: the market may be underestimating how long enterprises can remain in experimentation without abandoning AI spend entirely; that usually sustains compute and integration demand longer than consensus expects, while compressing expectations for “fast monetization” names. Falsifier: a visible step-up in AI-related bookings/revenue on upcoming earnings calls or a sudden reacceleration in enterprise software spend would invalidate the slow-adoption thesis.

Key Decisions for Investors

• Long IBM vs. short a high-multiple AI application basket (e.g., SNOW/CRM/PLTR) for 1-3 months: thesis is that enterprise buyers keep paying for modernization and trusted integration while postponing broad app-layer monetization; target relative outperformance if AI revenue conversion stays weak.
• Use any post-report pop in TDC to fade strength unless management follows with raised guidance or booking acceleration: the survey is supportive of demand tone, but not independently enough to justify multiple expansion without hard revenue proof.
• Maintain a tactical long bias in enterprise IT services / infrastructure over pure-play AI software for the next earnings season; this is a sector rotation call, not a single-name trade, and should be invalidated by clear evidence of faster AI budget conversion.
• Treat ANVS as a catalyst watch, not a conviction trade: do not add size on enrollment alone; reassess only around topline data or regulatory updates, since the stock remains driven by efficacy binary rather than operational milestones.